|
Market Closed -
Nasdaq
01:00:00 07/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 28.49 USD | +3.00% |
|
+2.78% | +6.39% |
| 11-07 | Amphastar Pharmaceuticals, Inc., Q3 2026 Earnings Call, Nov 05, 2026 | |
| 11-07 | Amphastar Pharmaceuticals Insider Sold Shares Worth $814,669, According to a Recent SEC Filing | MT |
Company Valuation: Amphastar Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,114 | 1,354 | 2,963 | 1,785 | 1,231 | 1,215 | - | - |
| Change | - | 21.52% | 118.8% | -39.75% | -31.07% | -1.25% | - | - |
| Enterprise Value (EV) 1 | 1,114 | 1,354 | 2,963 | 2,235 | 1,669 | 1,521 | 1,405 | 1,282 |
| Change | - | 21.52% | 118.8% | -24.56% | -25.34% | -8.85% | -7.64% | -8.78% |
| P/E | 18.6x | 16.1x | 23.8x | 12.1x | 13.2x | 13.1x | 10.8x | 11.5x |
| PBR | - | - | - | 2.41x | 1.55x | 1.38x | - | - |
| PEG | - | 0.4x | 0.5x | 0.7x | -0.4x | 1.9x | 0.5x | -1.9x |
| Capitalization / Revenue | 2.55x | 2.71x | 4.6x | 2.44x | 1.71x | 1.63x | 1.54x | 1.48x |
| EV / Revenue | 2.55x | 2.71x | 4.6x | 3.05x | 2.32x | 2.04x | 1.78x | 1.56x |
| EV / EBITDA | 11.2x | 9.21x | 10.4x | 7.18x | 6.74x | 7.14x | 6.51x | 6.17x |
| EV / EBIT | 14.5x | 11.1x | 12.1x | 8.66x | 7.73x | 8.44x | 7.5x | 6.41x |
| EV / FCF | - | 20.8x | - | 13x | 13.8x | 11.4x | 12.1x | 10.4x |
| FCF Yield | - | 4.81% | - | 7.71% | 7.26% | 8.81% | 8.26% | 9.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.25 | 1.74 | 2.6 | 3.06 | 2.03 | 2.17 | 2.64 | 2.48 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 437.8 | 499 | 644.4 | 732 | 719.9 | 747.3 | 790.4 | 821.5 |
| EBITDA 1 | 99.1 | 147.1 | 283.9 | 311.1 | 247.5 | 212.9 | 216 | 207.8 |
| EBIT 1 | 76.9 | 121.8 | 245.8 | 258.2 | 215.9 | 180.1 | 187.2 | 200 |
| Net income 1 | 62.12 | 91.39 | 137.5 | 159.5 | 98.09 | 99.32 | 115.4 | 111.1 |
| Net Debt 1 | - | - | - | 450 | 438.3 | 306 | 189.8 | 66.41 |
| Reference price 2 | 23.29 | 28.02 | 61.85 | 37.13 | 26.78 | 28.49 | 28.49 | 28.49 |
| Nbr of stocks (in thousands) | 47,849 | 48,331 | 47,907 | 48,081 | 45,952 | 42,652 | - | - |
| Announcement Date | 10/03/22 | 28/02/23 | 28/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.13x | 2.04x | 7.14x | -.--% | 1.22B | |
| 39.62x | 13.42x | 28.51x | 0.5% | 1,206B | |
| 40.43x | 6.79x | 19.09x | 1.93% | 665B | |
| 37.52x | 8.51x | 17.57x | 2.38% | 515B | |
| 20.98x | 5.12x | 12.74x | 2.57% | 381B | |
| 104.15x | 5.94x | 25.33x | 2.32% | 362B | |
| 23.47x | 5.94x | 14.26x | 2.69% | 307B | |
| 24.46x | 4.89x | 13.77x | 1.79% | 289B | |
| 23.75x | 7.3x | 13.55x | 2.19% | 249B | |
| -39.18x | 7.27x | 45.77x | 1.98% | 207B | |
| Average | 28.83x | 6.72x | 19.77x | 1.83% | 418.1B | |
| Weighted average by Cap. | 36.29x | 8.55x | 21.85x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AMPH Stock
- Valuation Amphastar Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
